KUCOIN
21.11.2023 11:01:29 CET | Business Wire | Press release
KuCoin, a top 5 cryptocurrency exchange platform, is empowering the future of payment with the launch of KuCard. This groundbreaking cryptocurrency debit card seamlessly merges digital assets with traditional banking, giving users the freedom to spend their cryptocurrency anywhere that accepts regular debit cards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231121892685/en/
KuCoin, a top 5 cryptocurrency exchange platform, is empowering the future of payment with the launch of KuCard. This groundbreaking cryptocurrency debit card seamlessly merges digital assets with traditional banking, giving users the freedom to spend their cryptocurrency anywhere that accepts regular debit cards. (Photo: Business Wire)
Accepted at millions of locations, KuCard empowers users to utilize their cryptocurrency for everyday purchases, online shopping, or even withdraw cash at ATMs. KuCard simplifies the process of converting and spending cryptocurrency, eliminating the complexities of transactions or conversions typically associated with digital assets. It automatically converts cryptocurrency into local currency at the point of sale, ensuring users always get the best possible exchange rate.
KuCard prioritizes the safety of digital assets with advanced security features. Real-time notifications and detailed transaction records help users easily track and manage spending, providing peace of mind that their digital assets are safe and secure. Additionally, KuCard seamlessly integrates with Apple Pay and Google Pay, enabling contactless payments using a smartphone. This integration not only provides an additional layer of convenience but also enhances the security of transactions.
In this first phase of the launch, KuCard will be exclusively available to residents of the European Economic Area (EEA), while a global launch is on the roadmap. To be eligible, users need to pass identity verification using a supported EEA-issued ID card. Users can immediately start using virtual KuCard for purchases after their applications are approved, and physical KuCard is available upon ordering. KuCard currently supports USDT and EUR. In the future, it will support a wide range of cryptocurrencies, giving users the freedom to use the cryptocurrency of their choice.
KuCard will offer a range of innovative features and rewards, including a cashback program allowing users to earn cryptocurrency with every purchase made using the card. To celebrate the first phase of launch, KuCoin is offering a special Black Friday promotion including unlimited cashback and a $2250 bonus.
"The launch of KuCard represents a significant milestone for both KuCoin and the cryptocurrency industry as a whole, as the daily payment method, the crypto debit card plays a crucial role in accelerating the crypto mass adoption" said Johnny Lyu, CEO at KuCoin. "We are excited to offer users a seamless bridge between digital assets and traditional banking, empowering them to spend their cryptocurrency with ease while enjoying the benefits of a traditional debit card."
Experience the convenience of a traditional debit card with the flexibility and potential of cryptocurrency. Embrace the future of payment with KuCard. For more information about KuCard and its features, please visit https://www.kucoin.com/kucard.
About KuCoin
Launched in September 2017, KuCoin is a global cryptocurrency exchange with its operational headquarters in Seychelles. As a user-oriented platform with a focus on inclusiveness and community action reach, it offers over 700 digital assets and currently provides spot trading, margin trading, P2P fiat trading, futures trading, staking, and lending to its 30 million users in more than 200 countries and regions. KuCoin is currently one of the top 5 crypto exchanges according to CoinMarketCap. In 2023, KuCoin was named one of the Best Crypto Exchanges by Forbes and recognized as a highly commended global exchange in Finder's 2023 Global Cryptocurrency Trading Platform Awards.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231121892685/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom